Search Results - "Ratner, E R"

The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes Among Women With and Without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow-Up by Aroda, V. R, Christophi, C. A, Edelstein, S. L, Zhang, P, Herman, W. H, Barrett-Connor, E, Delahanty, L. M, Montez, M. G, Ackermann, R. T, Zhuo, X, Knowler, W. C, Ratner, R. E, for the Diabetes Prevention Program Research Group

“…Context: Gestational diabetes (GDM) confers a high risk of type 2 diabetes. In the Diabetes Prevention Program (DPP), intensive lifestyle (ILS) and metformin…”
Get full text

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials by Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., Zinman, B.

“…Aim Hypoglycaemia and the fear of hypoglycaemia are barriers to achieving normoglycaemia with insulin. Insulin degludec (IDeg) has an ultra‐long and stable…”
Get full text

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial by Ratner, R. E., Rosenstock, J., Boka, G.

“…Diabet. Med. 27, 1024–1032 (2010) Aims  To evaluate the dose–response relationship of lixisenatide (AVE0010), a glucagon‐like peptide‐1 (GLP‐1) receptor…”
Get full text

Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study by Orchard, T. J., Temprosa, M., Barrett-Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., Saudek, C. D., Sherif, H., Watson, K. E.

“…Diabet. Med. 30, 46–55 (2013) Aims  Whether long‐term cardiovascular risk is reduced by the Diabetes Prevention Program interventions is unknown. The aim of…”
Get full text

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial by Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., Kolterman, O. G.

“…Aims  The autoimmune‐mediated destruction of pancreatic β‐cells in Type 1 diabetes mellitus renders patients deficient in two glucoregulatory peptide hormones,…”
Get full text

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes by Home, P. D., Meneghini, L., Wendisch, U., Ratner, R. E., Johansen, T., Christensen, T. E., Jendle, J., Roberts, A. P., Birkeland, K. I.

“…Diabet. Med. 29, 716–720 (2012) Aims  The efficacy and safety of insulin degludec (degludec), a new‐generation ultra‐long‐acting basal insulin, was compared…”
Get full text

Unrecognized diabetes among hospitalized patients by LEVETAN, C. S, PASSARO, M, JABLONSKI, K, KASS, M, RATNER, R. E

“…Unrecognized diabetes among hospitalized patients. C S Levetan , M Passaro , K Jablonski , M Kass and R E Ratner Medlantic Research Institute, Washington, DC…”
Get full text

Effect of physician specialty on outcomes in diabetic ketoacidosis by LEVETAN, C. S, PASSARO, M. D, JABLONSKI, K. A, RATNER, R. E

“…Effect of physician specialty on outcomes in diabetic ketoacidosis. C S Levetan , M D Passaro , K A Jablonski and R E Ratner MedStar Research Institute,…”
Get full text

Confirming Glycemic Status in the Diabetes Prevention Program: Implications for Diagnosing Diabetes in High Risk Adults by Christophi, C.A, Resnick, H.E, Ratner, R.E, Temprosa, M, Fowler, S, Knowler, W.C, Shamoon, H, Barrett-Connor, E, Kahn, S.E

“…Abstract Aims To examine the ability of fasting plasma glucose (FPG) and/or 2-h glucose to confirm diabetes and to determine the proportion of participants…”
Get full text

Pre-conception care of diabetes, congenital malformations, and spontaneous abortions by KITZMILLER, J. L, BUCHANAN, T. A, KJOS, S, COMBS, C. A, RATNER, R. E

Get full text

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus by Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., Kim, D. D.

“…Aim:  The ability of the incretin mimetic exenatide to improve glycaemic control and reduce body weight was assessed over 82 weeks in patients with type 2…”
Get full text

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial by Bray, G. A., Smith, S. R., Banerji, M. A., Tripathy, D., Clement, S. C., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R. E., Schwenke, D. C., Stentz, F. B., Reaven, P. D., DeFronzo, R. A.

“…Aims This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as…”
Get full text

Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance by Florez, H., Temprosa, M. G., Orchard, T. J., Mather, K. J., Marcovina, S. M., Barrett-Connor, E., Horton, E., Saudek, C., Pi-Sunyer, X. F., Ratner, R. E., Goldberg, R. B.

“…Aims To determine the association of metabolic syndrome (MetS) and its components with diabetes risk in participants with impaired glucose tolerance (IGT), and…”
Get full text

Fermi surface and electronic structure of Nd2-xCexCuO4-δ by KING, D. M, SHEN, Z.-X, RATNER, E. R, PENG, J. L, LI, Z. Y, GREENE, R. L, DESSAU, D. S, WELLS, B. O, SPICER, W. E, ARKO, A. J, MARSHALL, D. S, DICARLO, J, LOESER, A. G, PARK, C. H

Get full text

Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program by Hernan, William H, Brandle, Michael, Zhang, Ping, Williamson, David F, Matulik, Margaret J, Ratner, Robert E, Lachin, John M, Engelgau, Michael M

“…To describe the costs of the Diabetes Prevention Program (DPP) interventions to prevent or delay type 2 diabetes. We describe the direct medical costs, direct…”
Get full text

Presence of anti-pituitary hormone antibodies in patients with empty sella syndrome and pituitary tumours by Mau, M, Phillips, T M, Ratner, R E

“…We evaluated the presence of anti-pituitary hormone autoantibodies (APHA) in patients with primary empty sella syndrome and pituitary tumours and examined the…”
Get more information

Long-term health care outcomes in diabetes. Economic and political implications by Ratner, R E

“…With building pressure for cost-containment of medical expenditures, the medical community is finding it increasingly necessary to justify its procedures and…”
Get more information

Successful long-term kidney-pancreas transplants in diabetic patients with high C-peptide levels by SASAKI, T. M, GRAY, R. S, RATNER, R. E, CURRIER, C, AQUINO, A, BARHYTE, D. Y, LIGHT, J. A

“…Pancreas transplants are rarely done in type 2 (noninsulin dependent) diabetic patients. Most researchers believe that in type 2 diabetic patients, peripheral…”
Get full text

A quantitative measure of diabetes risk in community practice impacts clinical decisions: The PREVAIL initiative by Shah, B.R, Cox, M, Inzucchi, S.E, Foody, J.M, Zimmer, L.O, Jorge, C.B, Ratner, R.E, Barringer, T.A, McGuire, D.K, Peterson, E.D

“…Abstract Background and aims While predictive tools are being developed to identify those at highest risk for developing diabetes, little is known whether…”
Get full text

Summaries for patients. End-of-Life Planning intervention and the Completion of Advance Directives in homeless persons by Song, J, Ratner, E R, Wall, M M, Bartels, D M, Ulvestad, N, Petroskas, D, West, M, Weber-Main, A M, Grengs, L, Gelberg, L

Get full text